Concepedia

Sham S. Nikam

SS

Statistics

Publications

21

Citations

726

H-Index

18

Active since

1983

Affiliations

Pfizer (United States)(Current)

Gaertner (United States)

University of Arizona

Sham S. Nikam is an author at Pfizer (United States) specializing in pharmacology, medicinal chemistry, and natural sciences.

Publications per year

1983–2018

21

Publications

21

The cyclization of trimethylsilyl-substituted .alpha.-allenic alcohols to 3-(trimethylsilyl)-2,5-dihydrofurans and their facile autoxidation to 3-(trimethylsilyl)furans or 4-(trimethylsilyl)-2(5H)-furanones

Sham S. Nikam, Kai Hsuan Chu, Kung K. Wang · The Journal of Organic Chemistry · 1986 · 61 citations

, , +5

Phosphodiesterase 4 inhibition reduces lung fibrosis following targeted type II alveolar epithelial cell injury

Thomas H. Sisson, Paul J. Christensen, Yo Muraki et al. · Physiological Reports · 2018 · 58 citations · Full text

, , +12

Synthesis of hydroxamic acids: as a new catalyst for the deprotection of O-benzyl hydroxamates

Sham S. Nikam, Brian E Komberg, Donald R. Johnson et al. · Tetrahedron Letters · 1995 · 57 citations

, , +9

Evolution of schizophrenia drugs: a focus on dopaminergic systems.

Sham S. Nikam · PubMed · 2008 · 50 citations

, , +17

3-Arylimino-2-indolones Are Potent and Selective Galanin GAL<sub>3</sub> Receptor Antagonists

Michael J. Konkel, Bharat Lagu, Lakmal W. Boteju et al. · Journal of Medicinal Chemistry · 2006 · 49 citations · Full text

, , +9

1–5 of 21